Secukinumab Is Superior to Fumaric Acid Esters in Treating Subjects With Moderate to Severe Plaque Psoriasis Who Are Naïve to Systemic Treatments: Results From the Randomized Controlled PRIME Trial

British Journal of Dermatology - United Kingdom
doi 10.1111/bjd.15707
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Wiley

Related search

A 24‐week Multicentre, Randomised, Open‐label, Parallel‐group Study Comparing the Efficacy and Safety of Ixekizumab to Fumaric Acid Esters and Methotrexate in Patients With Moderate‐to‐severe Plaque Psoriasis Naïve to Systemic Treatment

British Journal of Dermatology
DermatologyMedicine
2020English

Fumaric Acid Esters in Combination With a 6-Week Course of Narrowband Ultraviolet B Provides an Accelerated Response Compared With Fumaric Acid Esters Monotherapy in Patients With Moderate-To-Severe Plaque Psoriasis: A Randomized Prospective Clinical Stud

British Journal of Dermatology
DermatologyMedicine
2018English

Randomized, Controlled Study of Bleselumab (ASKP1240) Pharmacokinetics and Safety in Patients With Moderate-To-Severe Plaque Psoriasis

Biopharmaceutics and Drug Disposition
MedicinePharmacologyPharmaceutical Science
2018English

Comparability of Trial Populations in Network Meta-Analyses Assessing Biologic Treatments in Moderate to Severe Plaque Psoriasis

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2014English

The Effect of Secukinumab on Moderate-To-Severe Scalp Psoriasis: Results of a 24-Week, Randomized, Double-Blind, Placebo-Controlled Phase 3b Study

Journal of the American Academy of Dermatology
Dermatology
2017English

Pss31 - Cost Per Responder of Secukinumab Compared to Other Biologics in Moderate-To-Severe Plaque Psoriasis From the Private Payer Perspective in Brazil

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Costs of Treatment in Patients With Moderate to Severe Plaque Psoriasis

Archives of Dermatology
2004English

Immunogenicity of Guselkumab Is Not Clinically Relevant in Patients With Moderate-To-Severe Plaque Psoriasis

Journal of Investigative Dermatology
BiochemistryDermatologyCell BiologyMolecular Biology
2019English

Population Pharmacokinetics of Brodalumab in Patients With Moderate to Severe Plaque Psoriasis

Basic and Clinical Pharmacology and Toxicology
MedicineToxicologyPharmacology
2019English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy